Driving business growth through innovative food and nutrition strategies for CPG & foodservice brands. 💡 The Rise of GLP-1 ...

A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

As revolutionary new weight-loss drugs turn consumers off ultraprocessed foods, the industry is on the hunt for new products.

Kennedy has promised to "Make America Healthy Again" by tackling obesity with nutrition. Here's how he could rattle the ...

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

Police looking for thieves who stole weight loss drugs from pharmacies in Dearborn, Dearborn Heights ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

As GLP-1 drugs like Ozempic soar in popularity for weight loss, this film follows three people on their own GLP-1 journeys and explores how decades of diet culture and society’s relentless pursuit of ...

Here’s the synopsis: As GLP-1 drugs like Ozempic soar in popularity for weight loss, this film follows three people on their ...

The COVID pandemic set in motion trends with alcohol use that have persisted. Disruptions in work, school and lifestyle have ...

About 140 million Americans, more than half of the nation's adults, could be considered candidates for weight loss drugs ...